Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

Rhea-AI Summary

Profound Medical Corp. (NASDAQ:PROF) has announced that CEO Arun Menawat will participate in a virtual panel on Focused Ultrasound at Cowen's 7th Annual FutureHealth Conference on June 23, 2022, at 9:55 a.m. ET. The discussion will not have a webcast but will be accessible to registered participants. Profound develops incision-free therapies for diseased tissue ablation, including TULSA-PRO® and Sonalleve®. TULSA-PRO® is FDA cleared and offers customizable prostate cancer treatments, while Sonalleve® treats uterine fibroids and bone metastases. Both technologies have various international approvals.

TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will participate in a virtual panel discussion on Focused Ultrasound hosted by Joshua Jennings, M.D., Managing Director, Health Care - Medical Supplies & Devices, at Cowen’s 7^th Annual FutureHealth Conference on Thursday, June 23, 2022 at 9:55 a.m. Eastern Time.

While the panel discussion will be accessible to registered conference participants, due to the format of the event, no webcast will be available.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO^® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO^® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

What is the date of the Profound Medical panel discussion?

The panel discussion featuring CEO Arun Menawat will take place on June 23, 2022.

Where will the Profound Medical panel discussion be held?

The discussion will be held virtually at Cowen's 7th Annual FutureHealth Conference.

What is TULSA-PRO® technology used for?

TULSA-PRO® is designed for customizable, incision-free prostate cancer treatments.

Is Sonalleve® approved for any treatments?

Yes, Sonalleve® is CE marked and FDA approved for treating uterine fibroids and bone metastases.

What stock symbol represents Profound Medical?

Profound Medical is listed under the stock symbol PROFESSIONAL (PROF).